Daewon Pharmaceutical (A003220) Stock Overview
A pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
A003220 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Daewon Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,780.00 |
| 52 Week High | ₩14,700.00 |
| 52 Week Low | ₩8,070.00 |
| Beta | 0.16 |
| 1 Month Change | -1.81% |
| 3 Month Change | -6.68% |
| 1 Year Change | -30.24% |
| 3 Year Change | -30.79% |
| 5 Year Change | -37.04% |
| Change since IPO | 114.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| A003220 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 19.0% | -6.5% | -7.9% |
| 1Y | -30.2% | 2.0% | 164.6% |
Return vs Industry: A003220 underperformed the KR Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: A003220 underperformed the KR Market which returned 164.6% over the past year.
Price Volatility
| A003220 volatility | |
|---|---|
| A003220 Average Weekly Movement | 11.0% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in KR Market | 15.9% |
| 10% least volatile stocks in KR Market | 4.4% |
Stable Share Price: A003220 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003220's weekly volatility has increased from 6% to 11% over the past year, but is still lower than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 1,283 | Seung-Ryel Baek | www.daewonpharm.com |
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease.
Daewon Pharmaceutical Co., Ltd. Fundamentals Summary
| A003220 fundamental statistics | |
|---|---|
| Market cap | ₩225.91b |
| Earnings (TTM) | -₩2.42b |
| Revenue (TTM) | ₩605.66b |
Is A003220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003220 income statement (TTM) | |
|---|---|
| Revenue | ₩605.66b |
| Cost of Revenue | ₩333.89b |
| Gross Profit | ₩271.77b |
| Other Expenses | ₩274.20b |
| Earnings | -₩2.42b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -112.99 |
| Gross Margin | 44.87% |
| Net Profit Margin | -0.40% |
| Debt/Equity Ratio | 66.6% |
How did A003220 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 08:19 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daewon Pharmaceutical Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Jiwon Lee | Heungkuk Securities Co., Ltd |
| Se Hoon Sohn | NH Investment & Securities Co., Ltd. |